A Phase 3 interventional study of Carbidopa/levodopa/entacapone and Immediate release carbidopa/levodopa in Parkinson's Disease, sponsored by Novartis Pharmaceuticals. Completed at 73 sites in 14 countries. Open to participants aged 30 Years to 70 Years. Per ClinicalTrials.gov, last updated 2012-04-23.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies testing carbidopa in Parkinson Disease — 1 open to participants now, 1 under way, none of them phase 3. Carbidopa · Parkinson Disease.
Among the 24 studies testing carbidopa in Parkinson Disease, this one has the largest enrollment, is one of 2 that started in 2004, is one of 7 in phase 3, and was the 1st registered.
4,578 studies on the registry are indexed under Parkinson Disease; 1,085 are open to participants now.
Browse Parkinson Disease studies →1 of the 24 studies testing carbidopa in Parkinson Disease is open now, in 1 country. Recruiting first, the newest first:
Second Affiliated Hospital of Soochow University · Sites in China
Ages 30–80
By country, each count listing its studies:
Carbidopa: first FDA approval 1975 (SINEMET), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →
Of the 748 Parkinson Disease studies recruiting now, 311 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: 30 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 5 · Phase 3 7 · Phase 4 9
First in 2004; this study’s year is marked. 2 started in 2004.
This study's enrollment of 747 is above the median of 40 across 3,357 interventional studies indexed under Parkinson Disease.
Median enrollment 46 across the 24 interventional studies. Of the 22 that completed or were terminated, 14 (64%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 24 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
21 studies in Parkinson Disease by Novartis: none open now, none under way, none of them phase 3. Of 20 finished, 5 (25%) have results posted.
Among the 21 studies in Parkinson Disease by Novartis, this one has the largest enrollment, is the only one that started in 2004, is one of 3 in phase 3, and was the 1st registered.
Novartis’s Parkinson Disease studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 24 studies testing carbidopa in Parkinson Disease, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 21 in Parkinson Disease:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The CELC200A2401 study has been designed in order to evaluate the hypothesis that administering the combination carbidopa/levodopa/entacapone at the time that levodopa therapy is initiated results in a decrease in the risk of the development of motor complications for patients with Parkinson's disease.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other inclusion/exclusion criteria applied to this study.
Patients received Carbidopa/levodopa/entacapone tablets. The study was designed as a flexible dose trial (200-1000 mg/day levodopa). The target dose was 400 mg/day levodopa administered orally as 4 equal doses 4 times a day with 3.5-hour dosing intervals for a treatment period of 134 to 208 weeks.
Drug: Carbidopa/levodopa/entacapone
Patients received Immediate release carbidopa/levodopa tablets. The study was designed as a flexible dose trial (200-1000 mg/day levodopa). The target dose was 400 mg/day levodopa administered orally as 4 equal doses 4 times a day with 3.5-hour dosing intervals for a treatment period of 134 to 208 weeks.
Drug: Immediate release carbidopa/levodopa
Drug pages: Carbidopa · Levodopa · Entacapone
Carbidopa/Levodopa/Entacapone 12.5/50/200 mg and 25/100/200 mg capsules.
Also known as: Stalevo
Immediate release carbidopa/levodopa 12.5/50 mg and 25/100 mg capsules.
Also known as: Sinemet
Time to First Occurrence of Dyskinesia
Dyskinesia was assessed by a blinded rater at each visit. Time to dyskinesia was defined as the visit at which the rater first answered "yes" to the following question: "In your opinion, does this patient have dyskinesia?" Time to dyskinesia was estimated by Kaplan-Meier product limit estimate that takes into consideration patients who did not experience dyskinesia by censoring them at the end of the study.
Time frame: Treatment duration for an individual patient varied between a minimum of 134 weeks for those patients recruited last and a maximum of 208 weeks for those patients recruited first
Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Total Score (Parts II and III)
The UPDRS is a standardized assessment scale used to measure the patient's disease state. It was to be completed by a blinded rater. There are 6 parts to the UPDRS. Part II (items 5-17; total score 0-52 units on the scale) measures the patient's activities of daily living and part III (items 18-31; total score 0-56 units on the scale) measures the motor function of the patient. The total score ranges from 0 to 108 units on the scale. A higher score indicates greater disability. A negative change score indicates improvement.
Time frame: Baseline, Week 6 and Week 130
Occurrence of Wearing-off
Wearing-off is defined as a perception of loss of mobility or dexterity, usually taking place gradually over minutes (up to an hour) and usually bearing a close temporal relationship to the timing of anti-parkinsonian medications; it does not include early-morning akinesia. To ascertain its occurrence, a blinded rater questioned the patient as to whether he/she had noticed that the benefits of the study drug were wearing-off.
Time frame: Baseline to Week 134
Time to First Occurrence of Wearing-off
Wearing off is defined as a perception of loss of mobility or dexterity, usually taking place gradually over minutes (up to an hour) and usually bearing a close temporal relationship to the timing of anti-parkinsonian medications; it does not include early-morning akinesia. To ascertain its occurrence, a blinded rater questioned the patient whether he/she had noticed that the benefits of the study drug wear-off. A motor complications and patient questionnaire card were provided to assist the blinded rater in determining whether a patient had experienced wearing-off.
Time frame: Baseline to end of study (134-208 weeks of treatment)
Occurrence of Dyskinesia
Dyskinesia was assessed by a blinded rater at each visit. Time to dyskinesia was defined as the visit at which the rater first answered "yes" to the following question: "In your opinion, does this patient have dyskinesia?"
Time frame: Baseline to Week 208
Change From Baseline in Health-related Quality of Life Assessed Using the 39-item Parkinson's Disease Questionnaire (PDQ-39)
The PDQ-39 instrument is used to assess quality of life in individuals with Parkinson's disease. The questionnaire provides scores on eight scales: Mobility, activities of daily living, emotions, stigma, social support, cognition, communication, and bodily discomfort. Questions are scored on a 5-point Likert scale ranging from 1 (never) to 3 (sometimes) to 5 (always). The total score can range from 39 to 190. A lower score indicates better quality of life. A negative change score indicates an improvement.
Time frame: Baseline to Week 156
| Milestone | Carbidopa/Levodopa/Entacapone | Carbidopa/Levodopa |
|---|---|---|
| Started | 374 | 373 |
| Intent-to-treat | 373 | 372 |
| Completed | 282 | 291 |
| Not completed | 92 | 82 |
| Withdrew: Withdrawal by subject | 46 | 28 |
| Withdrew: Adverse event | 19 | 19 |
| Withdrew: Protocol violation | 9 | 8 |
| Withdrew: Lost to follow-up | 6 | 4 |
| Withdrew: Lack of efficacy | 5 | 18 |
| Withdrew: Administrative problems | 4 | 4 |
| Withdrew: Death | 3 | 1 |
Dyskinesia was assessed by a blinded rater at each visit. Time to dyskinesia was defined as the visit at which the rater first answered "yes" to the following question: "In your opinion, does this patient have dyskinesia?" Time to dyskinesia was estimated by Kaplan-Meier product limit estimate that takes into consideration patients who did not experience dyskinesia by censoring them at the end of the study.
| weeks | Carbidopa/Levodopa/Entacapone | Carbidopa/Levodopa |
|---|---|---|
| Time to First Occurrence of Dyskinesia | 90.7 ± 47.9 | 117.1 ± 51.5 |
The UPDRS is a standardized assessment scale used to measure the patient's disease state. It was to be completed by a blinded rater. There are 6 parts to the UPDRS. Part II (items 5-17; total score 0-52 units on the scale) measures the patient's activities of daily living and part III (items 18-31; total score 0-56 units on the scale) measures the motor function of the patient. The total score ranges from 0 to 108 units on the scale. A higher score indicates greater disability. A negative change score indicates improvement.
| Units on a scale | Carbidopa/Levodopa/Entacapone | Carbidopa/Levodopa |
|---|---|---|
| Change from baseline to Week 6 | 21.9 ± 11.96 | 21.8 ± 11.24 |
| Change from baseline to Week 130 | 23.2 ± 13.38 | 22.8 ± 13.21 |
Wearing-off is defined as a perception of loss of mobility or dexterity, usually taking place gradually over minutes (up to an hour) and usually bearing a close temporal relationship to the timing of anti-parkinsonian medications; it does not include early-morning akinesia. To ascertain its occurrence, a blinded rater questioned the patient as to whether he/she had noticed that the benefits of the study drug were wearing-off.
| Participants | Carbidopa/Levodopa/Entacapone | Carbidopa/Levodopa |
|---|---|---|
| Occurrence of Wearing-off | 139 ± 45.6 | 161 ± 48.3 |
Wearing off is defined as a perception of loss of mobility or dexterity, usually taking place gradually over minutes (up to an hour) and usually bearing a close temporal relationship to the timing of anti-parkinsonian medications; it does not include early-morning akinesia. To ascertain its occurrence, a blinded rater questioned the patient whether he/she had noticed that the benefits of the study drug wear-off. A motor complications and patient questionnaire card were provided to assist the blinded rater in determining whether a patient had experienced wearing-off.
| Weeks | Carbidopa/Levodopa/Entacapone | Carbidopa/Levodopa |
|---|---|---|
| Time to First Occurrence of Wearing-off | 131.7 ± 3.8 | 129.5 ± 3.6 |
Dyskinesia was assessed by a blinded rater at each visit. Time to dyskinesia was defined as the visit at which the rater first answered "yes" to the following question: "In your opinion, does this patient have dyskinesia?"
| Participants | Carbidopa/Levodopa/Entacapone | Carbidopa/Levodopa |
|---|---|---|
| Occurrence of Dyskinesia | 128 ± 41.7 | 103 ± 32.4 |
The PDQ-39 instrument is used to assess quality of life in individuals with Parkinson's disease. The questionnaire provides scores on eight scales: Mobility, activities of daily living, emotions, stigma, social support, cognition, communication, and bodily discomfort. Questions are scored on a 5-point Likert scale ranging from 1 (never) to 3 (sometimes) to 5 (always). The total score can range from 39 to 190. A lower score indicates better quality of life. A negative change score indicates an improvement.
| Units on a scale | Carbidopa/Levodopa/Entacapone | Carbidopa/Levodopa |
|---|---|---|
| Change From Baseline in Health-related Quality of Life Assessed Using the 39-item Parkinson's Disease Questionnaire (PDQ-39) | 4.1 ± 12.06 | 1.8 ± 11.79 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Carbidopa/Levodopa/Entacapone | — | 91/373 (24.4%) | 310/373 (83.1%) |
| Carbidopa/Levodopa | — | 84/371 (22.6%) | 291/371 (78.4%) |
| Event | Carbidopa/Levodopa/Entacapone | Carbidopa/Levodopa |
|---|---|---|
| Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 9/373 | 2/371 |
| FallInjury, poisoning and procedural complications | 7/373 | 7/371 |
| Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 6/373 | 5/371 |
| Angina pectorisCardiac disorders | 2/373 | 5/371 |
| Intervertebral disc protrusionMusculoskeletal and connective tissue disorders | 4/373 | 5/371 |
| Myocardial infarctionCardiac disorders | 5/373 | 0/371 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 5/373 | 2/371 |
| Squamous cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/373 | 4/371 |
| NauseaGastrointestinal disorders | 0/373 | 3/371 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 1/373 | 3/371 |
| Event | Carbidopa/Levodopa/Entacapone | Carbidopa/Levodopa |
|---|---|---|
| NauseaGastrointestinal disorders | 114/373 | 70/371 |
| DiarrhoeaGastrointestinal disorders | 65/373 | 28/371 |
| DizzinessNervous system disorders | 59/373 | 46/371 |
| DepressionPsychiatric disorders | 57/373 | 51/371 |
| Back painMusculoskeletal and connective tissue disorders | 47/373 | 53/371 |
| InsomniaPsychiatric disorders | 47/373 | 53/371 |
| ConstipationGastrointestinal disorders | 50/373 | 44/371 |
| NasopharyngitisInfections and infestations | 34/373 | 43/371 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 38/373 | 43/371 |
| FatigueGeneral disorders | 40/373 | 42/371 |
| Age Continuous(years) | Carbidopa/Levodopa/Entacapone | Carbidopa/Levodopa | Total |
|---|---|---|---|
| Mean | 60.6 ± 8.67 | 59.8 ± 8.20 | 60.2 ± 8.44 |
| Sex: Female, Male(Participants) | Carbidopa/Levodopa/Entacapone | Carbidopa/Levodopa | Total |
|---|---|---|---|
| Female | 128 | 150 | 278 |
| Male | 245 | 222 | 467 |
The record gives a start of Sep 2004, a primary completion of Nov 2008 and a completion of Nov 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2011, 2 years 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Carbidopa · Levodopa · Entacapone